Early-stage biotech companies face a paradox. They drive the innovation pipeline, yet often collapse before reaching clinical trials—the infamous “valley of death.” While venture capital (VC) remains a key funding source, the industry’s mechanics are frequently misunderstood, particularly by first-time founders emerging from academia. Few people understand this intersection of medicine, finance, and innovation better … Navigating the Valley of Death: How Biotech Startups Can Survive Venture Capital Realities Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.